Last reviewed · How we verify

NCT06580639: MGIA

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

Recruiting now Last updated 30 August 2024
What this trial tests

trial testing No intervention. in Tuberculosis in 280 participants. Currently enrolling.

Timeline
1 August 2020
Primary endpoint
1 March 2025
1 December 2025

Quick facts

Lead sponsorLinkoeping University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment280
Start date1 August 2020
Primary completion1 March 2025
Estimated completion1 December 2025
Sites2 locations across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Linkoeping University

Who can join

18 and older, any sex, with Tuberculosis or Immunologic Activity Alteration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about how the blood leucocytes from patients with and without exposure or disease from tuberculosis (TB) are able to kill live mycobacteria (M. tuberculosis). The main question it aims to answer is: Is intracellular growth suppression of M. tuberculosis in peripheral blood mononuclear cells variable among healthy blood donors and higher than in patients with latent TB compared to active TB?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention.

Trials testing the same drug.

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

Other Linkoeping University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06580639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing